{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.021","pValueComment":"P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.194","pValueComment":"P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.012","pValueComment":"P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.449","pValueComment":"P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.578","pValueComment":"P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.140","pValueComment":"P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.266","pValueComment":"P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.074","value":"6.66"},{"groupId":"OG001","spread":"7.680","value":"4.15"},{"groupId":"OG002","spread":"7.378","value":"7.07"},{"groupId":"OG003","spread":"9.054","value":"7.00"},{"groupId":"OG004","spread":"6.733","value":"3.22"}]}],"title":"PCS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.983","value":"2.54"},{"groupId":"OG001","spread":"6.869","value":"1.89"},{"groupId":"OG002","spread":"7.898","value":"2.39"},{"groupId":"OG003","spread":"10.675","value":"3.03"},{"groupId":"OG004","spread":"10.437","value":"0.88"}]}],"title":"MCS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"97"}],"units":"Participants"}],"description":"The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains (physical functioning, bodily pain, role limitations due to physical problems and also emotional problems, general health, mental health, social functioning and vitality) and 2 component scores (PCS and MCS). The PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. The MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.","dispersionType":"Standard Deviation","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All randomized participants who received study drug in Part A and had SF-36 evaluated at analysis time point. LOCF was used to impute missing post-baseline values.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Mean Change From Baseline to Week 12 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores","type":"SECONDARY","unitOfMeasure":"units on a scale"}